" class="no-js "lang="en-US"> CellVax - Pharmtech Focus
Tuesday, January 31, 2023
Cellvax | Pharmtech Focus


About CellVax


CellVax Therapeutics is a privately held late-stage clinical trial company active in research, development, and innovation on autologous anticancer vaccines. CellVax Therapeutics has developed a proprietary autologous tumor cell-based cancer immuno-therapy platform. A pioneer in developing a therapy that aims to stimulate the immune system to recognize the abnormality of tumor cells and destroy them, the autologous cell vaccine is made from the tumor cells of the patient and generates a strong immune response.

Related Story

CellVax Selects Theragent as Manufacturing Partner for Phase 2 Clinical Trial for Prostate Cancer Immunotherapy

November 21 2022

Theragent, a cell therapy Contract Development and Manufacturing Organization (CDMO) focused on advancing next-generation cancer […]